Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease.
about
Rivastigmine for Alzheimer's diseaseRivastigmine for Alzheimer's diseaseRivastigmine for Alzheimer's diseaseSystematic Review: Representativeness of Participants in RCTs of Acetylcholinesterase InhibitorsEnhancing latent cognitive capacity in mild cognitive impairment with gist reasoning training: a pilot studyComparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer's disease.Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis.Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model.A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease.Preliminary findings of the effects of rivastigmine, an acetylcholinesterase inhibitor, on working memory in cocaine-dependent volunteersA rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia.A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.Comparing clinical profiles in Alzheimer's disease and Parkinson's disease dementia.Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review.Have last-observation-carried-forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review.Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.Transdermal patches for the treatment of neurologic conditions in elderly patients: a review.Rivastigmine from capsules to patch: therapeutic advances in the management of Alzheimer's disease and Parkinson's disease dementia.Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia.The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis.Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease.An update on the safety of current therapies for Alzheimer’s disease: focus on rivastigmine.A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.
P2860
Q24186551-6D97CFDD-3F9B-481D-9EA0-7112832C281CQ24187067-34C0E128-7784-4790-A4B5-1ACA35F3AE18Q24241686-255695F7-D99C-44AE-8F99-CA90B6B3AE4AQ26863383-587CE715-0591-4883-864A-71DB3DA57DE6Q33626154-F19A4737-4277-402C-B889-0099B4D420D8Q33937187-BA062321-318B-4217-BEF5-08F19B67FA99Q34051079-3A4879F0-CB0B-4555-8945-AA7D69D94633Q34487826-68533BEB-CB37-4B06-83AE-D0FC60AF5A53Q35428213-31DBFFC1-5091-49C2-A037-D0C7813F3773Q35609711-E6CA0FB0-9DA2-4145-A73A-7EA9D113FD67Q36998823-675C251A-DDD3-4C8E-B8BE-865B62999680Q37070395-AAFDBA82-BCBC-4B92-A3CC-8165A6889641Q37255114-D99158E6-CEEE-42E8-9D50-B36BB1646E30Q37325828-DD51F5B9-7758-4A3D-BBF0-76D7302FCFBBQ37396299-B9A6F04E-CABC-4671-9EF2-D5BC9DD9C68AQ37658872-7D3EA45D-AC91-44E0-8ED2-260EF4CD9654Q37997774-B41D0810-9809-4233-BE46-B88C2D859667Q38350602-B2D679C3-A401-4A11-82B5-B1DBE1EB1AB4Q38661735-E0FD0A20-62AD-45F6-A9F2-121E7C8F7EE2Q38672790-3A60D2DD-BBA1-427D-90DF-9F22F4E1DA30Q43099284-8948E1DE-B60E-440C-BB90-6C8BE296AB68Q50328399-1A56A8E8-1C71-46A8-B2A8-F440A4FB0991Q50799612-E36D40C5-0416-4ADF-83CC-28AD2D90264B
P2860
Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Rivastigmine: a placebo contro ...... ents with Alzheimer's disease.
@ast
Rivastigmine: a placebo contro ...... ents with Alzheimer's disease.
@en
type
label
Rivastigmine: a placebo contro ...... ents with Alzheimer's disease.
@ast
Rivastigmine: a placebo contro ...... ents with Alzheimer's disease.
@en
prefLabel
Rivastigmine: a placebo contro ...... ents with Alzheimer's disease.
@ast
Rivastigmine: a placebo contro ...... ents with Alzheimer's disease.
@en
P2860
P356
P1476
Rivastigmine: a placebo contro ...... ients with Alzheimer's disease
@en
P2093
Roger Lane
Study 304 Group
P2860
P304
P356
10.1136/JNNP.2006.099424
P407
P577
2007-03-12T00:00:00Z